STOCK TITAN

Medicinova Inc - MNOV STOCK NEWS

Welcome to our dedicated news page for Medicinova (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medicinova's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medicinova's position in the market.

Rhea-AI Summary
MediciNova receives $1 million milestone payment from Genzyme Corporation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
Rhea-AI Summary
MediciNova announces positive results from nonclinical studies on MN-166 as a potential treatment for chlorine gas-induced lung damage. MN-166 high dose showed a significant improvement in pulmonary function, with a 46% higher PaO2/FiO2 ratio compared to the negative control group. MN-166 has potential to treat acute lung disease from various causes. No efficacy results from the second nonclinical model study. Meeting with FDA planned for next steps.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
Rhea-AI Summary
MediciNova, Inc. announced that an abstract on tumor tissue analysis data from a clinical trial of MN-166 in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology. The poster will be presented by Dr. Justin Lathia, and the session is scheduled for November 17, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
MediciNova, Inc. has received a Notice of Intention to Grant from the European Patent Office for a pending patent application that covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis. The patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 in treating macular injury and decreasing macular volume loss associated with progressive multiple sclerosis. The patent also covers a wide range of doses and dosing frequencies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
none
-
Rhea-AI Summary
MediciNova, Inc. receives a new patent for MN-001 (tipelukast) for the treatment of scleroderma and/or systemic sclerosis, expected to expire no earlier than June 2035. The patent covers oral administration and a wide range of doses and dosing frequencies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.93%
Tags
none
-
Rhea-AI Summary
MediciNova, Inc. has received a Notice of Intention to Grant from the European Patent Office for a pending patent application covering MN-001 and MN-002 for the treatment of advanced nonalcoholic steatohepatitis (NASH). The allowed claims cover a wide range of doses and dosing frequencies. The patent is expected to expire no earlier than May 2035.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
Medicinova Inc

Nasdaq:MNOV

MNOV Rankings

MNOV Stock Data

77.00M
42.28M
2.56%
21.14%
0.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
La Jolla

About MNOV

pharmaceutical preparations